Try our beta test site
1 study found for:    NCT01012817
Show Display Options
Rank Status Study
1 Recruiting Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Conditions: Metastatic Malignant Solid Neoplasm;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Drug: Topotecan Hydrochloride;   Drug: Veliparib

Study has passed its completion date and status has not been verified in more than two years.